Biovitrum, Lundbeck deal

LUN's Synaptic Pharmaceutical Corp. subsidiary granted Biovitrum a license to its SMT-3 target, a G protein-coupled receptor (GPCR). Biovitrum plans to develop modulators of SMT-3 that promote insuli...